Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging

Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather than clinical symptoms. Therefore, it is of great interest to determine which biomarkers should be combined to ac...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuroimage Clin
Auteurs principaux: Ottoy, Julie, Niemantsverdriet, Ellis, Verhaeghe, Jeroen, De Roeck, Ellen, Struyfs, Hanne, Somers, Charisse, wyffels, Leonie, Ceyssens, Sarah, Van Mossevelde, Sara, Van den Bossche, Tobi, Van Broeckhoven, Christine, Ribbens, Annemie, Bjerke, Maria, Stroobants, Sigrid, Engelborghs, Sebastiaan, Staelens, Steven
Format: Artigo
Langue:Inglês
Publié: Elsevier 2019
Sujets:
Regular Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444289/
https://ncbi.nlm.nih.gov/pubmed/30927601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nicl.2019.101771
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires